P-117 CONTINUOUS INTRAVENOUS TACROLIMUS FOR LIVER TRANSPLANT RECIPIENTS: IMPLEMENTATION STRATEGY AND CLINICAL OUTCOMES
Conflict of interest: No Introduction and Objectives: Tacrolimus is the cornerstone of immunosuppression following liver transplantation (LT). In patients with prolonged orotracheal intubation, enteral administration (oral, nasogastric or sublingual) can result in variable pharmacokinetics and troug...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268124005143 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850168284490498048 |
|---|---|
| author | CAMILO ANDRES TORRES LONDOÑO ANDRES FERNANDO RODRIGUEZ GUTIERREZ Josefina Pages Alejandra Estefania Calizaya Astoraque Marcelo Silva Federico Piñero Martin Fauda MANUEL MENDIZABAL |
| author_facet | CAMILO ANDRES TORRES LONDOÑO ANDRES FERNANDO RODRIGUEZ GUTIERREZ Josefina Pages Alejandra Estefania Calizaya Astoraque Marcelo Silva Federico Piñero Martin Fauda MANUEL MENDIZABAL |
| author_sort | CAMILO ANDRES TORRES LONDOÑO |
| collection | DOAJ |
| description | Conflict of interest: No Introduction and Objectives: Tacrolimus is the cornerstone of immunosuppression following liver transplantation (LT). In patients with prolonged orotracheal intubation, enteral administration (oral, nasogastric or sublingual) can result in variable pharmacokinetics and trough levels. Continuous intravenous tacrolimus (CIT) may ensure a more stable dose-to-trough levels ratio. We aimed to describe an implementation strategy and outcomes of CIT in LT recipients. Patients / Materials and Methods: This case series includes consecutive adult LT patients receiving CIT at a single center from 2018 to 2024. CIT was administered to patients who could not receive enteral medication. The CIT dose ranged from 0.01 to 0.02 mg/kg/day, with adjustments based on the patient's clinical condition, and target blood trough levels 5-8 ng/ml. Clinical outcomes included acute cellular rejection, infections, renal and neurologic toxicities. Results and Discussion: Twelve patients received CIT, with a median initiation at 4 days (IQR: 2.5–19) post-LT. The median initial dose was 1 mg/24h (IQR: 0.7–1.0), Six (50%) patients achieved target trough levels at a median of 2.5 days (IQR: 1.5–4). Of the 12 patients, 11 had at least one tacrolimus trough level over 10 ng/ml, 7 had levels over 12 ng/ml, and 3 had levels over 15 ng/ml. The median duration of CIT was 12 days (IQR: 9–22). During CIT administration, complications included seizures (n=1), cytomegalovirus reactivation (n=4) and acute kidney injury (n=3). No cases of acute cellular rejection were observed, and 2 patients died during hospitalization, with deaths not related to CIT. Conclusions: This case series suggests that CIT is a feasible option with manageable toxicities for LT recipients unable to receive enteral medication, helping to prevent acute cellular rejection episodes. |
| format | Article |
| id | doaj-art-55d70e51c04b4e618d528aff03b62bc8 |
| institution | OA Journals |
| issn | 1665-2681 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj-art-55d70e51c04b4e618d528aff03b62bc82025-08-20T02:20:59ZengElsevierAnnals of Hepatology1665-26812024-12-012910173110.1016/j.aohep.2024.101731P-117 CONTINUOUS INTRAVENOUS TACROLIMUS FOR LIVER TRANSPLANT RECIPIENTS: IMPLEMENTATION STRATEGY AND CLINICAL OUTCOMESCAMILO ANDRES TORRES LONDOÑO0ANDRES FERNANDO RODRIGUEZ GUTIERREZ1Josefina Pages2Alejandra Estefania Calizaya Astoraque3Marcelo Silva4Federico Piñero5Martin Fauda6MANUEL MENDIZABAL7Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, ArgentinaGastrohepatology Unit, University of Antioquia, Medellín, ColombiaHepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, ArgentinaHepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, ArgentinaHepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, ArgentinaHepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, ArgentinaHepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, ArgentinaHepatology and Liver Transplant Unit, Hospital Universitario Austral, Pilar, ArgentinaConflict of interest: No Introduction and Objectives: Tacrolimus is the cornerstone of immunosuppression following liver transplantation (LT). In patients with prolonged orotracheal intubation, enteral administration (oral, nasogastric or sublingual) can result in variable pharmacokinetics and trough levels. Continuous intravenous tacrolimus (CIT) may ensure a more stable dose-to-trough levels ratio. We aimed to describe an implementation strategy and outcomes of CIT in LT recipients. Patients / Materials and Methods: This case series includes consecutive adult LT patients receiving CIT at a single center from 2018 to 2024. CIT was administered to patients who could not receive enteral medication. The CIT dose ranged from 0.01 to 0.02 mg/kg/day, with adjustments based on the patient's clinical condition, and target blood trough levels 5-8 ng/ml. Clinical outcomes included acute cellular rejection, infections, renal and neurologic toxicities. Results and Discussion: Twelve patients received CIT, with a median initiation at 4 days (IQR: 2.5–19) post-LT. The median initial dose was 1 mg/24h (IQR: 0.7–1.0), Six (50%) patients achieved target trough levels at a median of 2.5 days (IQR: 1.5–4). Of the 12 patients, 11 had at least one tacrolimus trough level over 10 ng/ml, 7 had levels over 12 ng/ml, and 3 had levels over 15 ng/ml. The median duration of CIT was 12 days (IQR: 9–22). During CIT administration, complications included seizures (n=1), cytomegalovirus reactivation (n=4) and acute kidney injury (n=3). No cases of acute cellular rejection were observed, and 2 patients died during hospitalization, with deaths not related to CIT. Conclusions: This case series suggests that CIT is a feasible option with manageable toxicities for LT recipients unable to receive enteral medication, helping to prevent acute cellular rejection episodes.http://www.sciencedirect.com/science/article/pii/S1665268124005143 |
| spellingShingle | CAMILO ANDRES TORRES LONDOÑO ANDRES FERNANDO RODRIGUEZ GUTIERREZ Josefina Pages Alejandra Estefania Calizaya Astoraque Marcelo Silva Federico Piñero Martin Fauda MANUEL MENDIZABAL P-117 CONTINUOUS INTRAVENOUS TACROLIMUS FOR LIVER TRANSPLANT RECIPIENTS: IMPLEMENTATION STRATEGY AND CLINICAL OUTCOMES Annals of Hepatology |
| title | P-117 CONTINUOUS INTRAVENOUS TACROLIMUS FOR LIVER TRANSPLANT RECIPIENTS: IMPLEMENTATION STRATEGY AND CLINICAL OUTCOMES |
| title_full | P-117 CONTINUOUS INTRAVENOUS TACROLIMUS FOR LIVER TRANSPLANT RECIPIENTS: IMPLEMENTATION STRATEGY AND CLINICAL OUTCOMES |
| title_fullStr | P-117 CONTINUOUS INTRAVENOUS TACROLIMUS FOR LIVER TRANSPLANT RECIPIENTS: IMPLEMENTATION STRATEGY AND CLINICAL OUTCOMES |
| title_full_unstemmed | P-117 CONTINUOUS INTRAVENOUS TACROLIMUS FOR LIVER TRANSPLANT RECIPIENTS: IMPLEMENTATION STRATEGY AND CLINICAL OUTCOMES |
| title_short | P-117 CONTINUOUS INTRAVENOUS TACROLIMUS FOR LIVER TRANSPLANT RECIPIENTS: IMPLEMENTATION STRATEGY AND CLINICAL OUTCOMES |
| title_sort | p 117 continuous intravenous tacrolimus for liver transplant recipients implementation strategy and clinical outcomes |
| url | http://www.sciencedirect.com/science/article/pii/S1665268124005143 |
| work_keys_str_mv | AT camiloandrestorreslondono p117continuousintravenoustacrolimusforlivertransplantrecipientsimplementationstrategyandclinicaloutcomes AT andresfernandorodriguezgutierrez p117continuousintravenoustacrolimusforlivertransplantrecipientsimplementationstrategyandclinicaloutcomes AT josefinapages p117continuousintravenoustacrolimusforlivertransplantrecipientsimplementationstrategyandclinicaloutcomes AT alejandraestefaniacalizayaastoraque p117continuousintravenoustacrolimusforlivertransplantrecipientsimplementationstrategyandclinicaloutcomes AT marcelosilva p117continuousintravenoustacrolimusforlivertransplantrecipientsimplementationstrategyandclinicaloutcomes AT federicopinero p117continuousintravenoustacrolimusforlivertransplantrecipientsimplementationstrategyandclinicaloutcomes AT martinfauda p117continuousintravenoustacrolimusforlivertransplantrecipientsimplementationstrategyandclinicaloutcomes AT manuelmendizabal p117continuousintravenoustacrolimusforlivertransplantrecipientsimplementationstrategyandclinicaloutcomes |